Redhill Biopharma
Yahoo Finance • 13 days ago
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
The inflammatory bowel disease market is experiencing sustained growth, driven by the rising prevalence of Crohn's disease and ulcerative colitis, increasing disease awareness, and earlier diagnosis. Additionally, the launch of emerging th... Full story
Yahoo Finance • 5 months ago
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap... Full story
Yahoo Finance • 8 months ago
RedHill Biopharma regains Nasdaq stockholders’ equity compliance
* RedHill Biopharma (RDHL [https://seekingalpha.com/symbol/RDHL]) has regained compliance [https://seekingalpha.com/pr/20323207-redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockholders-equity-requirement] with Nasdaq as... Full story
Yahoo Finance • 12 months ago
RedHill received Talicia licensing payments totaling $1.1 million
* RedHill Biopharma (NASDAQ:RDHL [https://seekingalpha.com/symbol/RDHL]) on Monday announced that it has received its first Talicia ex-U.S. sales milestone, royalties and other payments totaling approximately $1.1 million. * Talicia is... Full story
Yahoo Finance • last year
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index and the Health C PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 3 years ago
Morning Brew: Bank of America Predicts S&P 500 Upside, Kraft Heinz Approves $3B Buyback
Bank of America's global research team has outlined 10 key investment themes for 2024, forecasting a 10% rise in the S&P 500 (SP500), alongside potential interest rate cuts and Brent oil averaging $90 per barrel. The themes include a globa... Full story
Yahoo Finance • 3 years ago
RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders
RedHill commits to reimburse out-of-pocket costs for Talicia patients that complete the full 14-day treatment course and whose infection is not eradicated based on post-treatment confirmation testing - warranty commitment extends to all co... Full story
Yahoo Finance • 3 years ago
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
TEL AVIV, Israel and RALEIGH, NC, March 16, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it plans to implement a ratio change of the Co... Full story
Yahoo Finance • 3 years ago
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support UK MHRA scientific advice meeting deems RHB-102 (BEKINDA®) data supportive of submission for approval fo... Full story
Yahoo Finance • 3 years ago
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
UK MHRA scientific advice meeting deems RHB-102 (BEKINDA®) data supportive of submission for approval for chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV) RHB-102 UK Marketing Authorisation Application (MAA) submission... Full story
Yahoo Finance • 4 years ago
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
TEL AVIV, Israel & RALEIGH, N.C., Oct. 18, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announces that on October 12, 2022, it received a letter from the Li... Full story